Taken together, high MYBL2 is consistently associated with poorer patient prognosis in localized prostate cancer and mHSPC and leads to more aggressive cell lines and resistance to androgen deprivation and anti‐cancer therapies impacting cellular replication. Here, MYBL2 is linked to cancer.